Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naxitamab and GM-CSF in High-Risk Neuroblastoma
NCT03363373Phase 2Active, not recruiting
- Sponsor
- Y-mAbs Therapeutics, Inc.
- Start
- Apr 2018
- Primary completion
- Jun 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of naxitamab in neuroblastoma, sponsored by Y-mAbs Therapeutics, Inc.. Started Apr 2018; status: active, not recruiting.
02
Drugs
naxitamab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT03363373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03363373.